Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients.

Schlick, K; Kiem, D; Huemer, F; Neureiter, D; Weiss, L; Greil, R. Technol Cancer Res Treat. Jan-Dec 2021;20:15330338211042139. doi: 10.1177/15330338211042139.

A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report.

Steiner, M; Gassner, FJ; Parigger, T; Neureiter, D; Egle, A; Geisberger, R; Greil, R; Zaborsky, N. Int J Mol Sci. 2021 Aug 30;22(17):9410. doi: 10.3390/ijms22179410.

CAR T-Cell Therapy in Hematological Malignancies.

Haslauer, T; Greil, R; Zaborsky, N; Geisberger, R. Int J Mol Sci. 2021 Aug 20;22(16):8996. doi: 10.3390/ijms22168996.

Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.

Parigger, T; Gassner, FJ; Scherhaufl, C; Abu Bakar, A; Hopner, JP; Hodlmoser, A; Steiner, M; Catakovic, K; Geisberger, R; Greil, R; Zaborsky, N. Int J Mol Sci. 2021 Jun 22;22(13):6648. doi: 10.3390/ijms22136648.

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL.

Schubert, M; Gassner, FJ; Huemer, M; Hopner, JP; Akimova, E; Steiner, M; Egle, A; Greil, R; Zaborsky, N; Geisberger, R. Cancers (Basel). 2021 May 26;13(11):2619. doi: 10.3390/cancers13112619.

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.

Rauscher, S; Greil, R; Geisberger, R. Curr Cancer Drug Targets. 2021;21(4):353-359. doi: 10.2174/1568009620666210108102723.

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162.

Measurable residual disease in chronic lymphocytic leukemia: expert re-view and consensus recommendations.

Wierda, WG; Rawstron, A; Cymbalista, F; Badoux, X; Rossi, D; Brown, JR; Egle, A; Abello, V; Ceballos, EC; Herishanu, Y; Mulligan, SP; Niemann, CU; Diong, CP; Soysal, T; Suzuki, R; Tran, HTT; Wu, SJ; Owen, C; Stilgenbauer, S; Ghia, P; Hillmen, P. Leukemia. 2021 Jun 24. doi: 10.1038/s41375-021-01241-1. Online ahead of print.

Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.

Schlick, K; Markus, S; Huemer, F; Ratzinger, L; Zaborsky, N; Clemens, H; Neureiter, D; Neumayer, B; Beate, AS; Florian, S; Martin, V; Grundbichler, M; Weiss, L; Melchardt, T; Greil, R; Egle, A. Pancreatology. 2021 Sep 8;S1424-3903(21)00568-8. doi: 10.1016/j.pan.2021.09.004. Online ahead of print.

Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells.

Schamschula, E; Lahnsteiner, A; Assenov, Y; Hagmann, W; Zaborsky, N; Wiederstein, M; Strobl, A; Stanke, F; Muley, T; Plass, C; Tummler, B; Risch, A. Epigenetics. 2021 Aug 20;1-24. doi: 10.1080/15592294.2021.1959976. Online ahead of print.